Cesar Trillo Alvarez

CFF Center 26-27

CFF Center 25-26 - Trillo

CFF Center 24-25 - Trillo

CFF Center 23-24 - Trillo

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-710 in Adults with Cystic Fibrosis

A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability, and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

CFF Center 22-23 - Trillo

A Prospective Study Evaluating Maternal and FetaL Outcomes in the ERa of ModulatorS

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Beta-lactam continuous vs intermittent infusion and associated bacterial resistance and therapy outcomes in critically ill patients with severe pneumonia

CFF Center 21-22 - Trillo

A phase 1b randomized, double-blind, placebo-controlled trial to evaluate the safety of CB-280 in patients with cystic fibrosis

CF Center 20-21

CFF Center 19-20

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE II STUDY OF THE EFFICACY AND SAFETY OF LAU-7B IN THE TREATMENT OF CYSTIC FIBROSIS IN ADULTS

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

CFF Center 18-19

Program for Adult Care Excellence (PACE)